Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
M & A Strategy Supply Chain

Juno Looks To Shore Up Canada Supply Chains With Omega Deal

Juno Expects To Bring Over 100 New Products To The Canadian Market

  • News

Executive Summary

Quickfire M&A has been unveiled in Canada, with Juno Pharmaceuticals taking control of the former Nichi-Iko affiliate Omega Laboratories.

You may also be interested in...



Hikma Expands In Canada With Four New Injectables

Hikma has bolstered its generic sterile injectables business in Canada with four new launches.

Hikma Buys Teligent Assets To Expand Into Canada

Hikma has snapped up the Canadian sterile injectables assets of bankrupt Teligent in a $46m deal that marks Hikma’s first move into Canada.

Nichi-Iko Buys Sagent To Strengthen US Biosimilars Presence

Nichi-Iko Pharmaceutical Co. Ltd. will pay $736m in cash for Sagent Pharmaceuticals Inc. in a deal that will further expand the Japanese company's biosimilars business beyond Asia and diversify the US generics firm's injectable medicines portfolio.

Table

View full table

Topics

Tags:
M & A Strategy Supply Chain
Latest Headlines

Biocon Pumps Up For Adalimumab US Debut Amid Payer ‘Steady State’

Celltrion Makes Tocilizumab Progress With Positive Data At EULAR 2023

Samsung Bioepis Quiet On Launch Date After EU Soliris Biosimilar Approval

Is It Time To Promote US FDA’s Biosimilars Office Out Of OND?

See All
UsernamePublicRestriction

Register

GB152734

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By